16 results
424B3
PROK
ProKidney Corp - Ordinary Shares
21 Apr 23
Prospectus supplement
4:18pm
principal competitors include developers of SGLT2 inhibitors and Mineral Receptor Agonists (“MRAs”), which are small-molecule therapies recently … related to bone and mineral metabolism and hematopoiesis. Observations supporting this include trends toward decreasing phosphorus and increasing
POS AM
PROK
ProKidney Corp - Ordinary Shares
17 Apr 23
Prospectus update (post-effective amendment)
5:01pm
for kidney diseases are ongoing in Japan. We believe that our principal competitors include developers of SGLT2 inhibitors and Mineral Receptor … that injected SRCs may augment other important kidney functions related to bone and mineral metabolism and hematopoiesis. Observations supporting
424B3
PROK
ProKidney Corp - Ordinary Shares
9 Sep 22
Prospectus supplement
5:05pm
developers of SGLT2 inhibitors and Mineral Receptor Agonists (“MRAs”), which are small-molecule therapies recently approved to lower risks of CKD
DEFM14A
y3cnywi35uwrkfamjn
10 Jun 22
Proxy related to merger
4:54pm
DEFA14A
8w22nfkdwi77k a3
28 Apr 22
Additional proxy soliciting materials
8:02am
DEFA14A
EX-99.1
fedx47vhiwzj sszd
28 Apr 22
Additional proxy soliciting materials
8:02am
8-K
EX-99.1
6vm1sz8uuai
28 Apr 22
Regulation FD Disclosure
7:57am
PRER14A
7c7 zmsfvq
11 Apr 22
Preliminary revised proxy
5:29pm
PREM14A
it4fh5wg3t6gh89ibi
14 Feb 22
Preliminary proxy related to merger
4:55pm
DEFA14A
mnxg1cgv
18 Jan 22
Additional proxy soliciting materials
5:15pm
DEFA14A
0lcp4du
18 Jan 22
Additional proxy soliciting materials
7:14am
8-K
EX-99.2
ig44wy
18 Jan 22
Entry into a Material Definitive Agreement
7:05am
- Prev
- 1
- Next